The notified technical standard will be used in the registration process for biosimilar biotechnology medicines, to specify the provisions of MINSAL Supreme Decree No. 3/10 and establish the requirements to be met when submitting the health registration referred to in Article 42 (i).The purpose of this standard, which complements the regulations in force, is to provide internationally accepted requirements for the authorization of biosimilar products, that is, those declared to be similar to original biological products, which were authorized based on a complete quality, safety and efficacy dossier.This standard does not apply to vaccines, blood products, heparins or advanced therapies. These types of products have their own particularities, and there are national and international regulations that set out the registration requirements for these types of medicines.